Find information on thousands of medical conditions and prescription drugs.

X-linked severe combined immunodeficiency

X-linked severe combined immunodeficiency (SCID) is an inherited disorder of the immune system that occurs almost exclusively in males. Boys with X-linked SCID are prone to recurrent and persistent infections caused by certain bacteria, viruses, and fungi. These infections can be very serious or life-threatening. The organisms that cause infection in people with X-linked SCID are described as opportunistic because they ordinarily do not cause illness in healthy people. more...

X-linked adrenal...
X-linked ichthyosis
X-linked severe combined...
Xeroderma pigmentosum
XX male syndrome
XY Female

Many infants with X-linked SCID experience chronic diarrhea and skin rashes, and grow more slowly than other children. Without treatment, affected males usually do not live beyond infancy.


X-linked SCID is the most common form of severe combined immunodeficiency. The exact incidence is unknown, but the condition probably affects at least 1 in 50,000 to 100,000 births.


Mutations in the IL2RG gene cause X-linked severe combined immunodeficiency. The IL2RG gene provides instructions for making a protein that is essential to immune system function. This protein is necessary for the growth and maturation of developing immune system cells called lymphocytes. Lymphocytes defend the body against potentially harmful invaders, make antibodies, and help regulate the entire immune system. Mutations in the IL2RG gene prevent these cells from developing and functioning normally. Without functional lymphocytes, the body is unable to fight off infections.

This condition is inherited in an X-linked recessive pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder; this situation occurs only rarely. Therefore, males are affected by X-linked recessive disorders much more frequently than females.


[List your site here Free!]

Primary care and primary immunodeficiencies - Editorial
From American Family Physician, 11/15/03 by Kathleen E. Sullivan

In this issue of American Family Physician, Cooper and associates (1) provide a timely review of the diagnostic considerations of common primary immunodeficiencies. This is an exciting time in the field of immunology. It is worth reflecting on a few recent advances and highlighting the importance of maintaining a high index of suspicion for immunodeficiencies.

In 1997, the World Health Organization listed 60 primary immunodeficiencies. (2) An update in 1999 listed 71 defects of immunologic function and another 39 disorders in which immunodeficiency was a component. (3) Since that time, the genetic defects for most immunodeficiencies have been identified, and new disorders have been recognized at a rate of one to two per year.

The improved understanding of signaling pathways and mechanisms of host defense also has led to the development of interventions for primary immunodeficiencies. The most dramatic new management strategy is gene therapy for adenosine deaminase-deficient and X-linked forms of severe combined immunodeficiency. (4) The use of gene therapy remains somewhat controversial, but further refinements should improve its safety. Yet, the article by Cooper and colleagues (1) is a reminder that treatment advances are not helpful unless physicians can make the diagnosis early.

There is as yet no national database on primary immunodeficiencies. The most common diagnosis is IgA deficiency, with an estimated frequency of approximately one case per 500 white persons. (5) Excluding developmental delay of immunoglobulin production (transient hypogammaglobulinemia of infancy, which occurs in an estimated one of every 1,000 infants (5)), the next most common primary immunodeficiency is chromosome 22q11.2 deletion syndrome (DiGeorge syndrome). This syndrome occurs with an estimated frequency of one case per 3,000 live births, (6) regardless of ethnic or racial background.

Most family physicians can expect to encounter patients with primary immunodeficiencies. The most common primary immunodeficiencies would be seen in most large clinical practices. However, to ensure timely diagnosis, the family physician also should be familiar with the less common immunodeficiency disorders.

The article by Cooper and associates is important because it reminds the family physician to be alert to clinical presentations. With more than 70 disorders classified as congenital immunodeficiencies and other syndromes in which immunodeficiency is a significant component, it is somewhat overwhelming to attempt a thorough cataloging. Instead, it is helpful to remember that nearly all immunodeficiencies can be categorized according to the effector "arm" of the immune system that is impaired.

Patients with disorders of antibody production or function nearly always present with common recurrent infections. Each infection is unremarkable, but the frequency of the infections is excessive. Patients with common variable immunodeficiency (which becomes apparent later in life than other primary immunodeficiency disorders) typically present with new-onset recurrent sinusitis or bronchitis. Patients with antibody deficiencies usually do not look chronically ill.

The diagnosis of a disorder of antibody production or function nearly always will be suspected by the family physician, who has insight into a patient's pattern of visits for acute illnesses. Screening laboratory tests are readily obtainable and usually consist of immunoglobulin determinations and measurements of antibody responses to immunizations. Timely diagnosis of antibody defects is important, because untreated patients develop progressive end-organ damage and are at risk for life-threatening enteroviral infections.

Unlike patients with antibody disorders, who generally have typical infections, patients with T-cell defects often have unusual infections or atypical infections with common organisms. In children, T-cell defects are less common than antibody defects. In adults, T-cell defects (other than those resulting from human immunodeficiency virus [HIV] infection) seldom will be new diagnoses.

Recognition of patients with significant T-cell deficiencies is imperative, because delay of therapy adversely affects outcome. In infants, the frequencies of HIV infection and severe combined immunodeficiency are nearly the same. Thus, in most situations where HIV testing would be considered, primary T-cell defects also should be considered.

Although severe combined immunodeficiency may have various presentations, one key characteristic is the persistence of infection. In the absence of T-cell function, a simple upper respiratory tract infection progresses inexorably over one to two months. Hence, the family physician should be suspicious when an infant has an infection with a prolonged or atypical course.

A helpful finding is that most infants with severe combined immunodeficiency have diminished lymphocyte counts (less than 2,800 cells per [mm.sup.3] [2.8 3 [10.sup.9] per L]). An infant with chronic diarrhea, chronic wheezing, or recurrent Candida and a low lymphocyte count should be seen immediately by an immunologist. Urgent intervention is required for patients with severe combined immunodeficiency. Generally, the first step in analyzing these patients is to obtain lymphocyte counts, which often suggest the diagnosis of severe combined immunodeficiency.

Severe combined immunodeficiency nearly always is treated with stem cell transplantation. Polyethylene glycol-modified adenosine deaminase and gene therapy constitute reasonable experimental alternatives in certain patients. The success of all three treatments depends greatly on the status of the child at the time therapy is initiated. While stem cell transplantation or gene therapy is curative, an infant with severe end-organ compromise is less likely to survive the procedure. (7)

The primary immunodeficiencies with the least definable presentations are the phagocytic disorders. Most neutrophil disorders result in increased susceptibility to staphylococcal infections, whereas most macrophage activation disorders result in increased susceptibility to atypical mycobacterial infections. In addition, patients with neutrophil disorders often are predisposed to fungal and unusual bacterial infections. There are no easily obtainable screening tests for phagocytic disorders. Each disorder has its own specific diagnostic test.

The family physician is particularly well placed to recognize an abnormal infection pattern in a patient and initiate a work-up for suspected immunodeficiency disorder. Management of the patient with a primary immunodeficiency disorder requires a meticulous approach. Infections must be treated aggressively, and surveillance for unusual infections, malignancy, or autoimmune disease is critical. With appropriate medical support, the patient with a primary immunodeficiency disorder can be expected to lead a full and productive life.

Resources for patients, physicians, and caregivers are available through two organizations: the Immune Deficiency Foundation (http:// and The Jeffrey Modell Foundation (http://www.jmfworld. com).


(1.) Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician 2003;68: 2001-8,2011.

(2.) Primary immunodeficiency diseases. Report of a WHO scientific group. Clin Exp Immunol 1997; 109(suppl 1): 1-28.

(3.) Primary immunodeficiency diseases. Report of an IUIS scientific committee. International Union of Immunological Societies. Clin Exp Immunol 1999; 118(suppl 1):1-28.

(4.) Fischer A, Hacein-Bey S, Le Deist F, de Saint Basile G, Cavazzana-Calvo M. Gene therapy for human severe combined immunodeficiencies. Immunity 2001;15:1-4.

(5.) Stiehm ER. Immunologic disorders in infants and children. 4th ed. Philadelphia: Saunders, 1996.

(6.) Devriendt K, Fryns JP, Mortier G, van Thienen MN, Keymolen K. The annual incidence of DiGeorge/ velocardiofacial syndrome. J Med Genet 1998; 35:789-90.

(7.) Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Myers LA, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-16.

Kathleen E. Sullivan, M.D., Ph.D., is director of the immunology clinic at The Children's Hospital of Philadelphia.

Address correspondence to Kathleen E. Sullivan, M.D., Ph.D., Division of Immunology, The Children's Hospital of Philadelphia, 34th St. and Civic Center Blvd., Philadelphia, PA 19104. Reprints are not available from the author.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group

Return to X-linked severe combined immunodeficiency
Home Contact Resources Exchange Links ebay